PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
Details
Publication Year 2023-04,Volume 4,Issue #4,Page 535-549
Journal Title
Nature Cancer
Publication Type
Research article
Abstract
Invasive lobular breast cancer (ILC) is the second most common histological breast cancer subtype, but ILC-specific trials are lacking. Translational research revealed an immune-related ILC subset, and in mouse ILC models, synergy between immune checkpoint blockade and platinum was observed. In the phase II GELATO trial ( NCT03147040 ), patients with metastatic ILC were treated with weekly carboplatin (area under the curve 1.5 mg ml(-1) min(-1)) as immune induction for 12 weeks and atezolizumab (PD-L1 blockade; triweekly) from the third week until progression. Four of 23 evaluable patients had a partial response (17%), and 2 had stable disease, resulting in a clinical benefit rate of 26%. From these six patients, four had triple-negative ILC (TN-ILC). We observed higher CD8(+) T cell infiltration, immune checkpoint expression and exhausted T cells after treatment. With this GELATO trial, we show that ILC-specific clinical trials are feasible and demonstrate promising antitumor activity of atezolizumab with carboplatin, particularly for TN-ILC, and provide insights for the design of highly needed ILC-specific trials.
Publisher
Springer Nature
Keywords
Animals; Humans; Mice; B7-H1 Antigen; Carboplatin/therapeutic use; *Carcinoma, Lobular/drug therapy/pathology; *Triple Negative Breast Neoplasms/drug therapy/pathology
Department(s)
Laboratory Research
PubMed ID
37038006
Open Access at Publisher's Site
https://doi.org/10.1038/s43018-023-00542-x
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-07 07:16:22
Last Modified: 2023-08-07 07:17:40

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙